Adverum Biotechnologies Appoints Mike Fitzgerald as Vice President, Human Resources
“Mike is a valuable addition to our leadership team,” said
“I am excited to join the Adverum team,” said
Mr. Fitzgerald has over 23 years of experience leading successful and effective teams. Prior to joining Adverum, Mr. Fitzgerald was the Senior Vice President, Global Human Resources for ZELTIQ Aesthetics (now
Mr. Fitzgerald earned a bachelor’s degree in Political Science from the
On the date Mr. Fitzgerald commenced his employment with Adverum, the Company granted Mr. Fitzgerald a stock option to purchase 190,000 shares of Adverum common stock pursuant to the inducement grant exception under Nasdaq Rule 5635(c)(4), as an inducement that is material to Mr. Fitzgerald entering employment with Adverum. The option has a per share exercise price equal to the closing sales price of Adverum’s common stock on Nasdaq on the grant date, and will vest over four years, subject to his continued service with Adverum.
About Adverum Biotechnologies, Inc.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Katherine BockVice President Investor Relations & Corporate Communications Adverum Biotechnologies, Inc.650-656-9347 firstname.lastname@example.org
Source: Adverum Biotechnologies, Inc.